Cart
sales@molnova.com
(3α,4β)-3-(Acetyloxy)ursa-5,12-dien-23-oic acid
CAS No. 1649436-95-2
(3α,4β)-3-(Acetyloxy)ursa-5,12-dien-23-oic acid( ——— )
Catalog No. M38419 CAS No. 1649436-95-2
3α-Acetoxyurs-5:12-dien-24-oic acid is a natural product that can be isolated from Boswellia sacra Fluckiger.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | Get Quote | Get Quote |
|
| 50MG | Get Quote | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product Name(3α,4β)-3-(Acetyloxy)ursa-5,12-dien-23-oic acid
-
NoteResearch use only, not for human use.
-
Brief Description3α-Acetoxyurs-5:12-dien-24-oic acid is a natural product that can be isolated from Boswellia sacra Fluckiger.
-
Description3α-Acetoxyurs-5:12-dien-24-oic acid is a natural product that can be isolated from Boswellia sacra Fluckiger.
-
In Vitro———
-
In Vivo———
-
Synonyms———
-
PathwayOthers
-
TargetOther Targets
-
Recptor———
-
Research Area———
-
Indication———
Chemical Information
-
CAS Number1649436-95-2
-
Formula Weight496.72
-
Molecular FormulaC32H48O4
-
Purity>98% (HPLC)
-
Solubility———
-
SMILES———
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Ali L, et al. Two new and four known triterpenoids from Boswellia sacra fluckiger. Records of Natural Products, 2014, 8(4): 407.
molnova catalog
related products
-
FUBP1-IN-1
FUBP1 - in-1, with an IC50 value of 11.0 M, is an effective FUSE binding protein 1 (FUBP1) inhibitor that can interfere with the binding of FUBP1 to its SINGLE-strand target DNA FUSE sequence.
-
Sacituzumab
Sacituzumab is a humanized IgG1 monoclonal antibody utilized in the synthesis of antibody-active small-molecule couplings (naked antibody to Sacituzumab govitecan).
-
Deferasirox
An oral iron chelator that used to reduce chronic iron overload; also induces apoptosis in myeloid leukemia cells by targeting caspase.
